131I Ablation of an Entire Thyroid Gland in Locally Invasive Differentiated Thyroid Cancer Without Surgery

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Grace Yung ◽  
Nicholas Forwood ◽  
Robert Russo ◽  
Kirtan Ganda ◽  
Robert Mansberg
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Gland ◽  
Differentiated Thyroid Cancer ◽  
131I Ablation

Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)

2007 ◽  
Vol 46 (05) ◽  
pp. 213-219 ◽  
Author(s):  
J. Dressler ◽  
W. Eschner ◽  
F. Grünwald ◽  
M. Lassmann ◽  
B. Leisner ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
131I Therapy ◽  
131I Ablation ◽  
Procedure Guidelines ◽  
Lower Blood ◽  
Higher Sensitivity

SummaryThe procedure guideline for radioiodine therapy (RIT) of differentiated thyroid cancer (version 3) is the counterpart to the procedure guideline for 131I whole-body scintigraphy (version 3) and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Recommendation for ablative 131I therapy is given for all differentiated thyroid carcinoma (DTC) >1 cm. Regarding DTC ≤1 cm 131I ablation may be helpful in an individual constellation. Preparation for 131I ablation requires low iodine diet for two weeks and TSHstimulation by withdrawal of thyroid hormone medication or by use of recombinant human TSH (rhTSH). The advantages of rhTSH (no symptoms of hypothyroidism, lower blood activity) and the advantages of endogenous TSHstimulation (necessary for 131I-therapy in patients with metastases, higher sensitivity of 131I whole-body scan) are discussed. In most centers standard activities are used for 131I ablation. If pretherapeutic dosimetry is planned, the diagnostic administration of 131I should not exceed 1–10 MBq, alternative tracers are 123I or 124I. The recommendations for contraception and family planning are harmonized with the recommendation of ATA and ETA. Regarding the best possible protection of salivary glands the evidence is insufficient to recommend a specific setting. To minimize the risk of dental caries due to xerostomia patients should use preventive strategies for dental hygiene.

Differentiated thyroid microcarcinoma − current perspective

2020 ◽  
Vol 99 (11) ◽  
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Thyroid Gland ◽  
Retrospective Analysis ◽  
Differentiated Thyroid Cancer ◽  
Good Prognosis ◽  
Wilcoxon Test ◽  
Nodal Involvement ◽  
Thyroid Microcarcinoma ◽  
Current Perspective

Introduction: Differentiated thyroid cancer (DTC) has a good prognosis and low mortality despite its growing incidence, which is particularly the case of microcarcinomas (T1a – up to 10 mm). Methods: Retrospective analysis of overall survival of patients in the group of thyroid gland surgeries for differentiated forms of microcarcinoma in the period of 2006–2015 up to the present. An overview of contemporary therapeutic methods is included. Results: Thyroid cancer was detected in 144 cases out of the total of 1820 patients with thyreopathy undergoing surgery (8%); DTC microcarcinoma was detected in 65 cases (45.1%) of all carcinomas. The papillary form was diagnosed in 59 cases (51.8% of all papillary cases), and the follicular form was found in 6 cases (37.5% of all follicular cases). Two cases of Hürthle cells cancer were found, both in a stage higher than T1. Overall 10-year survival of carcinomas >T1 was 86%, reaching 90% in the microcarcinoma group (Gehan Wilcoxon test: p=0.10675). Conclusion: Differentiated microcarcinoma shows a very good overall survival. Provided that other criteria are satisfied, particularly unifocal occurrence without spreading through the gland casing and without any suspicion of nodal involvement, hemithyroidectomy is considered to be a sufficient procedure or the method of choice, respectively.

scholarly journals The Success Rate of Initial 131I Ablation in Differentiated Thyroid Cancer: Comparison Between Less Strict and Very Strict Low Iodine Diets

2011 ◽  
Vol 46 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Ik Dong Yoo ◽  
Sung Hoon Kim ◽  
Ye Young Seo ◽  
Jin Kyoung Oh ◽  
Joo Hyun O ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Success Rate ◽  
Differentiated Thyroid Cancer ◽  
131I Ablation

Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients

2015 ◽  
Vol 54 (04) ◽  
pp. 151-157 ◽  
Author(s):  
M. Winter ◽  
J. Winter ◽  
A. Heinzel ◽  
F. F. Behrendt ◽  
T. Krohn ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Whole Body ◽  
Whole Body Scan ◽  
Body Scan ◽  
Therapeutische Maßnahmen ◽  
131I Ablation

ZusammenfassungZiel: Beantwortung der Frage, ob drei Monate nach 131I-Ablation als zu früh für eine diagnostische Radioiod-Ganzkörperszintigraphie (dxWBS) bei Patienten mit einem differenzierten Schilddrüsenkarzinom (DTC) anzusehen sind. Patienten, Material, Methode: Daten von 462 DTC-Patienten, die in unserem Klinikum behandelt worden waren, wurden analysiert. Alle Patienten wurden thyreoid ektomiert. Von 129 Patienten waren folgende Daten verfügbar a) eine dxWBS mit gleichzeitiger TSH-stimulierter Thyreoglobulin-Messung, die innerhalb von vier Monaten (max. 120 Tage) nach 131I-Ablation durchgeführt wurde ohne weitere therapeutische Maßnahmen zwischen Ablation und dxWBS, b) eine zweite dxWBS oder 131I-Therapie (rxWBS), die innerhalb von 1,5 Jahren nach Ablation durchgeführt wurde. Ergebnisse: Bei 25/129 Patienten stimmten die Ergebnisse der initialen und weiteren Scans nicht überein: Bei 15 von 54 Patienten (27%) mit einem positiven initialen dxWBS widersprachen diese Ergebnisse dem zweiten dxWBS oder rxWBS. Neue Läsionen wurden bei 10/74 (14%) Patienten mit einem initial negativen dxWBS entdeckt. Eine Diskordanz zwischen dem ersten und weiteren in der Nachsorge gemessenen stimulierten Tg-Werten wurde in 5/129 (4%) der Patienten gefunden: Bei 2/90 (2%) Patienten mit einer negativen ersten stimulierten Tg-Bestimmung wurde nachfolgend ein positives Ergebnis gefunden. Bei 3/29 (10%) Patienten mit einer positiven ersten Bestimmung wurde bei der zweiten Untersuchung ein negatives Ergebnis festgestellt. Schlussfolgerung: Weniger als vier Monate nach 131I-Ablation ist zu früh für eine diagnostische Radioiod-Ganzkörperszintigraphie mit zeitgleich TSH-stimulierter Tg-Messung. Die Ermittlung des richtigen späteren Zeitpunkts erfordert weitere Untersuchungen.Das Zeitintervall zwischen 131I Ablation und diagnostischer Ganzkörperszintigraphie bei Patienten mit differenziertem Schilddrüsenkarzinom Weniger als vier Monate nach Ablation dürfte zu früh sein

Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer

Surgery ◽  
2004 ◽  
Vol 136 (6) ◽  
pp. 1275-1280 ◽  
Author(s):  
Guy Leblanc ◽  
Roger Tabah ◽  
Moishe Liberman ◽  
John Sampalis ◽  
Rami Younan ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Differentiated Thyroid Cancer ◽  
131I Ablation ◽  
Well Differentiated

Thyroid papillary cancer-related pregnancy: a case report

2017 ◽  
Vol 6 (1) ◽  
Author(s):  
Burak Giray ◽  
Esra Esim Buyukbayrak ◽  
Omer Talip Turhan ◽  
Ayse Yasemin Karageyim Karsidag
Keyword(s):  
Breast Cancer ◽  
Thyroid Cancer ◽  
Thyroid Gland ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Malignancy ◽  
Papillary Cancer ◽  
Thyroid Papillary ◽  
Thyroid Papillary Cancer ◽  
Neck Lymph Nodes ◽  
In Pregnancy

Abstract Differentiated thyroid cancer is the second-most frequent tumor among those tumors diagnosed during pregnancy after breast cancer; it also is the most common endocrine malignancy. Pregnancy-associated cancer was defined as a malignancy detected during pregnancy or within 2 years of delivery, but most of the patients with pregnancy-associated cancer were recognized in the postpartum period. The best time for surgery is unclear. Its management is a challenge for both doctors and patients. Enlargement of the thyroid gland in pregnancy is usually a physiological change related to pregnancy, but even if it is rare, it can be due to thyroid malignancy. We report a case of 31-year-old female diagnosed with thyroid papillary cancer during pregnancy with no symptoms except for a lump on her neck. For this reason, the examination of the thyroid gland and the examination of neck lymph nodes should be routinely performed on all pregnant women.

No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer

2009 ◽  
Vol 37 (2) ◽  
pp. 276-283 ◽  
Author(s):  
Frederik Anton Verburg ◽  
Marcel P. M. Stokkel ◽  
Christian Düren ◽  
Robbert B. T. Verkooijen ◽  
Uwe Mäder ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
High Risk ◽  
Differentiated Thyroid Cancer ◽  
Low Risk ◽  
131I Ablation ◽  
Survival Difference
Sign in / Sign up

Export Citation Format

Share Document